Boyuan Capital
博原资本
Boyuan Capital (博远资本, also referenced as BioTrack Capital) is a healthcare-focused investment fund. According to a 2023 FreeS Fund article, it co-led the Series A of DeepKinase alongside Longpan Investment . The fund has also been cited as a follow-on investor in Aureka Biotechnologies' Series A+ in 2026 , and as a continuing backer of AnKuo Biopharma and an angel-round investor in Inming Biotech in 2021 .
elsewhere's corpus does not contain a dedicated profile of Boyuan Capital's founding, team, or fund size — the references above name it only as a participant in specific deals.
AI-generated — may contain errors, please verify.
Coverage
CATL Leads Galaxy Universal's New 1.1 Billion Yuan Funding Round | BlueRun Ventures Portfolio
Achieve industrial breakthroughs with unwavering determination
2024, When Everyone Stands at a Crossroads: 96 Investors' Decisions
Deciding is easy. Waiting is hard.
138-Year-Old Bosch Goes Deep on an Industrial Capital Experiment | Ruqiju
"Entering the Game" is a regular column from *Dark Tides Waves*. It grew out of our observation that once-reliable operating models are facing new challenges, and the industry rules inherited from West to East have been disrupted. People urgently need a new map and new order for innovation and capital. "Entering the game" itself is the most precious posture of all. **"Entering the Game" was born amid transformation.** If we had to summarize this column's subject in one sentence: we hope to find the new [cut off]
